The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial
Open accessAbstract
Background Preeclampsia complicates approximately 3% to 5% of pregnancies and remains a major cause of maternal and neonatal morbidity and mortality. It shares pathogenic similarities with adult cardiovascular disease as well as many risk factors. Pravastatin, a hydrophilic, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor, has been shown in preclinical studies to reverse various pathophysiological pathways associated with preeclampsia, providing biological plausibility for its use for preeclampsia prevention. However, human trials are lacking. Objective As an initial step in evaluating the utility of pravastatin in preventing preeclampsia, and after consultation with the U.S. Food and Drug Administration, we undertook a pilot randomized controlled trial with the objective to determine pravastatin safety and pharmacokinetic parameters when used in pregnant women at high risk of preeclampsia. Study Design We conducted a pilot, multicenter, double-blind, placebo-controlled, randomized trial of women with singleton, non-anomalous pregnancies at high risk for preeclampsia. Women between 120/7 and 166/7 weeks gestation were assigned to daily pravastatin 10 mg or placebo orally until delivery. Primary outcomes were maternal-fetal safety and pharmacokinetic parameters of pravastatin during pregnancy. Secondary outcomes included rates of preeclampsia and preterm delivery, gestational age at delivery, birthweight, and maternal and cord blood lipid profile (Clinicaltrials.gov Identifier NCT01717586). Results Ten women assigned to pravastatin and ten to placebo completed the trial. There were no differences between the two groups in rates of study drug side effects, congenital anomalies, or other adverse or serious adverse events. There was no maternal, fetal, or neonatal death. Pravastatin renal clearance was significantly higher in pregnancy compared to postpartum. Four subjects in the placebo group developed preeclampsia compared to none in the pravastatin group. Although pravastatin reduced maternal cholesterol concentrations, umbilical cord cholesterol concentrations and infant birthweight were not different between the groups. The majority of umbilical cord and maternal pravastatin plasma concentrations at time of delivery were below the lower limit of quantification of the assay. Conclusions This study provides preliminary safety and pharmacokinetic data regarding the use of pravastatin for preventing preeclampsia in high-risk pregnant women. Although the data are preliminary, no identifiable safety risks were associated with pravastatin use in this cohort. This favorable risk-benefit analysis justifies using pravastatin in a larger clinical trial with dose escalation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
(2013) · doi:10.1097/01.aog.0000437382.03963.88 · Cited by 3,961
Onuegbu, A. J., Olisekodiaka, J. M., Udo, J. U., Umeononihu, O., Amah, U. K., Okwara, J. E., & Atuegbu, C. (2015) · Medical Principles and Practice · doi:10.1159/000381778 · Cited by 2,044
Practice bulletin #33: diagnosis and management of preeclampsia and eclampsia
ACOG Committee on Obstetric Practice (2002) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(01)01747-1 · Cited by 1,058
Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data
Askie, L. M., Duley, L., Henderson-Smart, D. J., & Stewart, L. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60712-0 · Cited by 1,020
Brugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792
Young, B. C., Levine, R. J., & Karumanchi, S. A. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102149 · Cited by 719
Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study
Hernandez-Diaz, S., Toh, S., & Cnattingius, S. (2009) · BMJ · doi:10.1136/bmj.b2255 · Cited by 566
Mongraw-Chaffin, M. L., Cirillo, P. M., & Cohn, B. A. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.150078 · Cited by 434
Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments
Mills, E. J., Rachlis, B., Wu, P., Devereaux, P. J., Arora, P., & Perri, D. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.039 · Cited by 423
Cited by
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Pre-eclampsia: pathophysiology and clinical implications
Burton, G. J., Redman, C. W., Roberts, J. M., & Moffett, A. (2019) · BMJ · doi:10.1136/bmj.l2381 · Cited by 1,250
Pre-eclampsia: pathogenesis, novel diagnostics and therapies
Phipps, E. A., Thadhani, R., Benzing, T., & Karumanchi, S. A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0119-6 · Cited by 1,191
Chappell, L. C., Cluver, C. A., Kingdom, J., & Tong, S. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32335-7 · Cited by 925
Metadata
- Authors
- Costantine, M. M., Cleary, K., Hebert, M. F., Ahmed, M. S., Brown, L. M., Ren, Z., Easterling, T. R., Haas, D. M., Haneline, L. S., Caritis, S. N., Venkataramanan, R., West, H., D’Alton, M., & Hankins, G.
- Venue
- American Journal of Obstetrics and Gynecology
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 214
- Issue
- 6
- Pages
- 720.e1-720.e17
- ISSN
- 0002-9378 (ISSN-L)
- OpenAlex
- W2210639700
- Cited by
- 275
- References
- 36
- FWCI
- 22.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. https://app.cochat.ai/papers/10.1016/j.ajog.2015.12.038
- The paper
- Costantine, M. M., Cleary, K., Hebert, M. F., Ahmed, M. S., Brown, L. M., Ren, Z., Easterling, T. R., Haas, D. M., Haneline, L. S., Caritis, S. N., Venkataramanan, R., West, H., D’Alton, M., & Hankins, G. (2016). Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2015.12.038
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.